194,916 Shares in Artivion, Inc. (NYSE:AORT) Acquired by Point72 Asset Management L.P.

Point72 Asset Management L.P. purchased a new position in Artivion, Inc. (NYSE:AORT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 194,916 shares of the company's stock, valued at approximately $5,573,000. Point72 Asset Management L.P. owned approximately 0.46% of Artivion at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Wasatch Advisors LP lifted its holdings in Artivion by 27.7% in the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after purchasing an additional 226,160 shares in the last quarter. Next Century Growth Investors LLC lifted its holdings in Artivion by 29.7% in the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock worth $14,085,000 after purchasing an additional 112,918 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Artivion by 10.0% during the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company's stock worth $13,244,000 after acquiring an additional 42,170 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Artivion by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company's stock worth $10,241,000 after acquiring an additional 8,343 shares in the last quarter. Finally, Oberweis Asset Management Inc. raised its holdings in shares of Artivion by 10.8% during the 4th quarter. Oberweis Asset Management Inc. now owns 312,900 shares of the company's stock worth $8,946,000 after acquiring an additional 30,500 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AORT. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of Artivion in a report on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price objective on Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Finally, Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $31.40.

Artivion Stock Performance

NYSE:AORT opened at $29.61 on Tuesday. The stock's fifty day moving average is $24.76 and its 200 day moving average is $27.33. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $32.33. The firm has a market capitalization of $1.26 billion, a PE ratio of -1,480.50 and a beta of 1.54. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Activity at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 10,548 shares of the company's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $29.13, for a total value of $307,263.24. Following the transaction, the senior vice president now owns 105,332 shares of the company's stock, valued at $3,068,321.16. This represents a 9.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James P. Mackin sold 42,156 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the transaction, the chief executive officer now directly owns 663,882 shares in the company, valued at $18,130,617.42. This trade represents a 5.97% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,347 shares of company stock worth $2,663,486. Company insiders own 7.60% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.